Abstract
Adoptive immunotherapy is considered a promising strategy for the treatment of metastatic tumors and current research efforts are directed to define the optimal approach and facilitate the transferability from preclinical to clinical settings. Among several approaches it is possible to schematically distinguish strategies based on either MHC-restricted or MHC-unrestricted immune effectors. The first are mainly based on the infusion of tumor-specific T lymphocytes capable of recognizing determined MHC-restricted tumor associated antigens (TAA) through their T cell receptor. MHC-unrestricted approaches do not target specific tumor associated antigens and are mainly mediated by effectors of the innate immune system, like natural killer (NK) cells or NKT cells, first barrier against pathogens and tumorigenesis processes, or by ex vivo activated lymphocytes like cytokine-induced killer (CIK) cells. MHC-unrestricted effectors are usually more abundant than TAA-specific precursors and easier to expand. Furthermore their activity is not restricted to precise HLAhaplotypes, not limited to a single tumor histotype and could overcome downregulation of MHC molecules operated by tumor cells as immune escape mechanism.
In this review we will discuss the main cancer immunotherapy strategies based on MHC-unrestricted immune effectors. The topic will be approached from the angle of ex vivo expansion protocols in clinical prospective, as well as potential approaches to favorably modulate their functions.
Keywords: Adoptive immunotherapy, MHC-unrestricted activity, NK, CIK, NKT.
Anti-Cancer Agents in Medicinal Chemistry
Title:Ex Vivo-Activated MHC-Unrestricted Immune Effectors for Cancer Adoptive Immunotherapy
Volume: 14 Issue: 2
Author(s): Valeria Leuci, Giulia Mesiano, Loretta Gammaitoni, Maja Todorovic, Lidia Giraudo, Fabrizio Carnevale-Schianca, Massimo Aglietta and Dario Sangiolo
Affiliation:
Keywords: Adoptive immunotherapy, MHC-unrestricted activity, NK, CIK, NKT.
Abstract: Adoptive immunotherapy is considered a promising strategy for the treatment of metastatic tumors and current research efforts are directed to define the optimal approach and facilitate the transferability from preclinical to clinical settings. Among several approaches it is possible to schematically distinguish strategies based on either MHC-restricted or MHC-unrestricted immune effectors. The first are mainly based on the infusion of tumor-specific T lymphocytes capable of recognizing determined MHC-restricted tumor associated antigens (TAA) through their T cell receptor. MHC-unrestricted approaches do not target specific tumor associated antigens and are mainly mediated by effectors of the innate immune system, like natural killer (NK) cells or NKT cells, first barrier against pathogens and tumorigenesis processes, or by ex vivo activated lymphocytes like cytokine-induced killer (CIK) cells. MHC-unrestricted effectors are usually more abundant than TAA-specific precursors and easier to expand. Furthermore their activity is not restricted to precise HLAhaplotypes, not limited to a single tumor histotype and could overcome downregulation of MHC molecules operated by tumor cells as immune escape mechanism.
In this review we will discuss the main cancer immunotherapy strategies based on MHC-unrestricted immune effectors. The topic will be approached from the angle of ex vivo expansion protocols in clinical prospective, as well as potential approaches to favorably modulate their functions.
Export Options
About this article
Cite this article as:
Leuci Valeria, Mesiano Giulia, Gammaitoni Loretta, Todorovic Maja, Giraudo Lidia, Carnevale-Schianca Fabrizio, Aglietta Massimo and Sangiolo Dario, Ex Vivo-Activated MHC-Unrestricted Immune Effectors for Cancer Adoptive Immunotherapy, Anti-Cancer Agents in Medicinal Chemistry 2014; 14 (2) . https://dx.doi.org/10.2174/18715206113136660371
DOI https://dx.doi.org/10.2174/18715206113136660371 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Role of natural compounds as anti anti-cancer agents
Cancer is considered the leading cause of worldwide mortality, accounting for nearly 10 million deaths in 2022. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy remains an important approach in treatment o f several types of cancers, even though ...read more
Signaling and enzymatic modulators in cancer treatment
Cancer accounts for nearly 10 million deaths in 2022 and is considered the leading cause of worldwide mortality. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy, radiotherapy and surgery are the most important approach for the treatment of several ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Plant Polysaccharides with Immunostimulatory Activities
Current Organic Chemistry MicroRNAs Determining Inflammation as Novel Biomarkers and Potential Therapeutic Targets
Current Medicinal Chemistry Developmental Expression and Dysregulation of miR-146a and miR-155 in Down's Syndrome and Mouse Models of Down's Syndrome and Alzheimer's Disease
Current Alzheimer Research Discovery and Development of Hepatitis C Virus Inhibitors Targeting the NS5A Protein
Mini-Reviews in Medicinal Chemistry A Recent Update on the Epigenetic Repertoire and Chromatin Modifying Therapy in Diabetes Mellitus: A Comprehensive Review
Current Medicinal Chemistry Melatonin and Hypothalamic-Pituitary-Gonadal Axis
Current Medicinal Chemistry Activity of Drugs and Components of Natural Origin in the Severe Myoclonic Epilepsy of Infancy (Dravet Syndrome)
Central Nervous System Agents in Medicinal Chemistry Gut Microbiota Modulation and Mucosal Immunity: Focus on Rifaximin
Mini-Reviews in Medicinal Chemistry Immunity Modulators, Repurposed Drugs and Candidate Vaccines for COVID-19: A Review
Coronaviruses Synthesis, p38 Kinase Inhibitory and Anti-inflammatory Activity of New Substituted Benzimidazole Derivatives
Medicinal Chemistry An Epigenetic Approach to Pancreatic Cancer Treatment: The Prospective Role of Histone Deacetylase Inhibitors
Current Cancer Drug Targets Involvement of Breast Cancer-Associated Fibroblasts in Tumor Development, Therapy Resistance and Evaluation of Potential Therapeutic Strategies
Current Medicinal Chemistry G Protein-Coupled Receptor Kinase 2 - a Feedback Regulator of Gq Pathway Signalling
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Antibody Functional Assays as Measures of Fc Receptor-Mediated Immunity to HIV - New Technologies and their Impact on the HIV Vaccine Field
Current HIV Research Targeted Tumor Therapies at a Glance
Current Drug Targets HIV Infection and Myocardial Infarction
Current HIV Research Editorial [ Cardiovascular Risk Factor Modification: A sine qua non in the Management of Vascular Surgery Patients ]
Current Vascular Pharmacology Suppression of Protein Aggregation by L-Arginine
Current Pharmaceutical Biotechnology Medicinal Chemistry of Drugs with Active Metabolites Following Conjugation
Mini-Reviews in Medicinal Chemistry Cough in Respiratory and Autoimmune Disorders
Current Respiratory Medicine Reviews